Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 1292-1298

  Tanaka, Tetsuji ^a   Bai, Tao ^b   Toujima, Saori ^c   Utsunomiya, Tomoko ^c   Matsuoka, Toshihide ^c   Kobayashi, Aya ^c   Yamamoto, Madoka ^c   Sasaki, Noriyuki ^c   Tanizaki, Yuko ^c   Utsunomiya, Hirotoshi ^c   Tanaka, Junko ^d   Yukawa, Kazunori ^e  

^a Santamaria Hospital   (Japan)

^b UNIVERSITY OF CHICAGO   (United States)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d KOBE UNIVERSITY   (Japan)

^e MEIJO UNIVERSITY   (Japan)

Author keywords

Cervical carcinoma; CPT 11; Death associated protein kinase; Drug resistance; Methylation; SN38; Squamous cell carcinoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; DEATH ASSOCIATED PROTEIN KINASE; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DAPK GENE; DEMETHYLATION; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MARKER GENE; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS REGULATORY PROTEINS; AZACITIDINE; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DEALKYLATION; DNA MODIFICATION METHYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC; UTERINE CERVICAL NEOPLASMS;

EID: 84863011953     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1628     Document Type: Article

References (39)

1. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4192, 1991.
2. Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, et al: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58: 31-37, 2000. (Pubitemid 30045307)
3. Umesaki N, Fujii T, Nishimura R, Tanaka T, Nishida M, Fushiki H, Takizawa K, Yamamoto K, Hasegawa K and Izumi R: Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol 95: 127-132, 2004. (Pubitemid 39286287)
4. Tanaka T, Kokawa K and Umesaki N: Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: a pilot study. Eur J Gynaec Oncol 26: 605-607, 2005. (Pubitemid 43028052)
5. Tanaka T, Umesaki N and Ogita S: Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases. Eur J Gynaec Oncol 11: 377-379, 2000.
6. Nishino K, Aoki Y, Amikura T, Obata H, Sekine M, Yahata T, Fujita K and Tanaka K: Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. Gynecol Oncol 97: 893-897, 2005. (Pubitemid 40824662)
7. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002. (Pubitemid 34438898)
8. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Eng J Med 343: 905-914, 2000.
9. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alaki M, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
10. Yamao T, Shirao K, Matsumura Y, Muro K, Yamada Y, Goto M, Chin K and Shimada Y: Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Ann Oncol 12: 1729-1735, 2001. (Pubitemid 34105663)
11. Tobinai K and Hotta T: Clinical trials for malignant lymphoma in Japan. Jpn J Clin Oncol 34: 369-378, 2004. (Pubitemid 43115299)
12. Tanaka, T, Utsunomiya T, Utsunomiya H and Umesaki N: Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women. Oncol Rep 19: 1123-1133, 2008.
13. Deiss LP, Feinstein E, Berissi H, Cohen O and Kimchi A: Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 9: 15-30, 1995.
14. 2+/ calmodulin-dependent, cytoskeleton-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J 16: 998-1008, 1997.
15. Kissil JL, Feinstein E, Cohen O, Jones PA, Tsai YC, Knowles MA, Eydmann ME and Kimchi A: DAP kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene 15: 403-407, 1997. (Pubitemid 27370989)
16. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L and Kimchi A: DAP kinase links the control of apoptosis to metastasis. Nature 390: 180-184, 1997. (Pubitemid 27507988)
17. Cohen O, Inbal B, Kissil JL, Raveh T, Berissi H, Spivak-Kroizaman T, Feinstein E and Kimchi A: DAP kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 146: 141-148, 1999. (Pubitemid 29349970)
18. Jang CW, Chen CH, Chen CC, Chen JY, Su YH and Chen RH: TGFβ induces apoptosis through Smad-mediated expression of DAP kinase. Nat Cell Biol 4: 51-58, 2002. (Pubitemid 34071980)
19. Raveh T, Droguett G, Horwitz MS, De Pinho RA and Kimchi A: DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 3: 1-7, 2001. (Pubitemid 32114825)
20. Pelled D, Raveh T, Riebeling C, Fridkin M, Berissi H, Futerman AH and Kimchi A: Death-associated protein (DAP) kinase plays a central role in ceramide induced apoptosis in cultured hippocampal neurons. J Biol Chem 277: 1957-1961, 2002. (Pubitemid 34968774)
21. Yamamoto M, Hioki T, Nakajima-Iijima S and Uchino S: DAP kinase activity is critical for C (2)-ceramide-induced apoptosis in PC12 cells. Eur J Biochem 269: 139-147, 2002. (Pubitemid 34107347)
22. Wang WJ, Kuo JC, Yao CC and Chen RH: DAP kinase induces apoptosis by suppressing integrin activity and disrupting matrix survival signals. J Cell Biol 159: 169-179, 2002.
23. Jin Y, Blue EK, Dixon S, Hou L, Wysolmerski RB and Gallagher PJ: Identification of a new form of death-associated protein kinase that promotes cell survival. J Biol Chem 276: 39667-39678, 2001.
24. Jin Y and Gallagher PJ: Antisense depletion of death-associated protein kinase promotes apoptosis. J Biol Chem 278: 51587-51593, 2003. (Pubitemid 38020402)
25. Bai T, Tanaka T, Yukawa K and Umesaki N: Reduced expression of death-associated protein kinase in human uterine and ovarian carcinoma cells. Oncol Rep 11: 661-665, 2003.
26. Li L, Tanaka T, Yukawa K, Akira S and Umesaki N: Irinotecan-induced ovarian follicular apoptosis is attenuated by deleting the kinase domain of death-associated protein kinase. Int J Oncol 34: 905-914, 2009.
27. Bai T, Tanaka T and Yukawa K: Targeted knockdown of death-associated protein kinase expression induces TRAIL-mediated apoptosis in human endometrial adenocarcinoma cells. Int J Oncol 37: 203-210, 2010.
28. Tanaka T, Bai T and Yukawa K: Death-associated protein kinase is essential for the survival of various types of uterine cancer cells. Int J Oncol 37: 1017-1022, 2010.
29. Bai T, Tanaka T, Yukawa K and Umesaki N: A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2′-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells. Int J Oncol 28: 497-508, 2006.
30. Tanaka T, Bai T and Yukawa K: Suppressed protein expression of death-associated protein kinase enhances 5-fluorouracil-sensitivity but not etoposide-sensitivity in human endometrial adenocarcinoma cells. Oncol Rep 24: 1401-1405, 2010.
31. Tanaka T: Establishment and characterization of the SN38-resistant sublines from human cervical SCC. J Jpn Soc Gynecol Oncol 20: 210-215, 2002.
32. Tanaka T, Yukawa K and Umesaki N: Combination effects of irradiation and irinotecan on cervical squamous cell carcinoma cells in vitro. Oncol Rep 14: 1365-1369, 2005.
33. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG and Anthoney DA: hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15: 45-52, 1997. (Pubitemid 27348095)
34. Strathdee G, MacKean MJ Ill and Mand Brown R: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335-2341, 1999. (Pubitemid 29192710)
35. Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB and Brown R: Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 18: 87-93, 2000. (Pubitemid 30036340)
36. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002. (Pubitemid 34587077)
37. Frost P, Abbruzzese JL, Hunt B, Lee D and Ellis M: Synergistic cytotoxicity using 2′-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Cancer Res 50: 4572-4577, 1990. (Pubitemid 20230394)
38. Zhang X, Yashiro M, Ohira M, Ren J and Hirakawa K: Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Cancer Sci 97: 938-944, 2006. (Pubitemid 44151277)
39. Crea F, Giovannetti E, Cortesi F, Mey V, Nannizzi S, Gallegos Ruiz MI, Ricciardi S, Del Tacca M, Peters GJ and Danesi R: Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol Cancer Ther 8: 1964-1973, 2009.